Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Melanoma 1Leiomyosarcoma 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 361Pemetrexed 276Cisplatin 230Paclitaxel 213Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 129Radiotherapy 114Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 82atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 50Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27aflutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × rubitecan × Clear all
NCT00005872 2013-12-04

Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡